Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors

Veteran Life Sciences Executive and Investor Brings 35+ Years’ Experience

Marizyme, Inc., a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced that it has appointed veteran life sciences executive and investor Dr. Neil J. Campbell, as CEO and President and a member of its Board of Directors.

Dr. Campbell has more than 35 years of successful experience with public and private companies in the life sciences, medical, health tech, nanotechnology, artificial intelligence, and high-performance computing technologies, including with IGEN International (now Roche), Celera Genomics, and Abbott Laboratories. He also has prior institutional investment experience as a partner in venture capital and operating partner and industry advisor in private equity.

Recommended AI News: Proactive Vs Reactive: Eliminating Passive Safety Systems With New Technology Trends

James Sapirstein, Marizyme’s Executive Chairman, who also served as Interim CEO, commented, “Neil is a strong leader who will take Marizyme to the next level by advancing the company’s clinical programs and develop strategies and execution to unlock shareholder value.  His extensive executive experience in the life sciences and medical industries, as well as his investment background, will guide Marizyme as the company grows its life science assets and seeks to elevate its financial position.”

“I am very excited to join the Marizyme team,” said Dr. Campbell. “Marizyme has great potential in the pipeline of products in development and the early success of products like DuraGraft®, which has been shown to reduce graft failure in bypass surgery and significantly reduce major adverse cardiac events such as repeat revascularization and myocardial infarction.”

Recommended AI News: Hot Startups : Latest News and Updates on Daily Roundup

Dr. Campbell currently serves as Chairman of Mosaigen®, a commercial development company, and RespaRx™, a medical device company. Previously, Dr. Campbell served as Chairman, CEO, and founder of Celios®, a respiratory device company that was acquired by a private investment group. Prior to founding Celios, Dr. Campbell was Co-founder, President and CEO of Helomics, a personalized healthcare company focused on next-generation therapeutics and diagnostics.

Dr. Campbell has held senior executive positions at SuperNova Diagnostics, EntreMed Pharmaceuticals, Life Technologies, IGEN International (now Roche), Celera Genomics, and Abbott Laboratories. He has also held academic positions at Johns Hopkins University and Medical Institutes, Hong Kong University of Science and Tech, University of Liverpool (UK), University of Baltimore and Duquesne University in Pittsburgh, PA.

Dr. Campbell earned his B.S. from Norwich University; his M.A. and M.B.A. from Webster University; and his Doctorate from the University of Liverpool in the UK.

Recommended AI News: Proactive Vs Reactive: Eliminating Passive Safety Systems With New Technology Trends

Leave A Reply

Your email address will not be published.